AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held by AngioDynamics, Inc. on November 3, 2021. The company is incorporated in Delaware and its common stock trades on the NASDAQ Global Select Market under the symbol ANGO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes were reported in this filing. The document details the outcomes of shareholder votes regarding board composition, auditor ratification, and executive compensation.
Outlook, Risks, and Voting Results
Shareholders approved all three proposals presented at the meeting:
- Board Election: Wesley E. Johnson Jr. and Karen A. Licitra were elected as Class III directors to serve until the 2024 Annual Meeting.
- Auditor Ratification: The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending May 31, 2022, was ratified.
- Executive Compensation: The advisory proposal to approve the compensation of named executive officers was approved.
Key Facts for Investor Verification
- Wesley E. Johnson Jr. received 30,749,937 votes for, while Karen A. Licitra received 33,059,728 votes for.
- The auditor ratification proposal received 35,367,874 votes for approval with only 32,374 votes against.
- The executive compensation advisory vote received 32,326,421 votes for approval, with 998,582 votes against.
- There were 2,070,027 broker non-votes recorded for the director elections and the executive compensation proposal.